Idarubicin Phares

Idarubicin Hydrochloride, the active ingredient in Idarubicin Phares, is an anthracycline antibiotic presented as an injectable solution for intravenous use. It treats acute myeloid leukemia in adult patients.

GNH USA supplies Idarubicin Phares as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Idarubicin Phares is an anthracycline used in the treatment of acute leukemias. - Acute Myeloid Leukemia (AML): induces remission in newly diagnosed or relapsed disease. - Acute Lymphoblastic Leukemia (ALL): incorporated into combination regimens for induction therapy. - Myelodysplastic syndromes progressing to AML: employed in selected cases to achieve disease control.

Idarubicin Phares may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during treatment. - Myelosuppression: reduced white blood cells and platelets. - Alopecia: hair loss affecting scalp and body hair. - Fatigue: persistent tiredness during therapy.

Serious or Rare Side Effects: - Cardiotoxicity: potential for reduced heart function or heart failure. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Hemorrhage: bleeding complications due to thrombocytopenia.

When using Idarubicin Phares, clinicians should observe several safety measures to minimize risks. - Cardiac monitoring: perform baseline and periodic echocardiograms to assess ejection fraction. - Hematologic surveillance: regularly check complete blood counts for neutropenia and thrombocytopenia. - Liver function assessment: evaluate hepatic enzymes and adjust use in impairment. - Avoid concurrent cardiotoxic agents: limit exposure to other drugs that affect the heart. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Idarubicin Phares can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Other cardiotoxic drugs (e.g., doxorubicin, trastuzumab): increase risk of heart damage. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise idarubicin plasma levels. - Live vaccines: immunosuppression can lead to uncontrolled infection.

Moderate Interactions (Monitor Closely): - Myelosuppressive agents (e.g., cytarabine): may enhance bone‑marrow toxicity. - Anticoagulants (e.g., warfarin): heightened bleeding tendency. - Nephrotoxic medications (e.g., cisplatin): require renal function monitoring.